Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 21/1/2020
SIETES contiene 92882 citas

 1 a 20 de 124 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med 2019;179:agosto. [Ref.ID 103160]
2. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
4. Cita con resumen
Anónimo. Drugs for psychotic disorders. The Medical Letter on Drug and Therapeutics Bulletin 2016;58:160-4. [Ref.ID 101042]
5.Enlace a cita original Cita con resumen
Oteri A, Mazzaglia G, Pecchioli S, Molokhia M, Ulrichsen SP, Pedersen L, Poluzzi E, De Ponti F, Garbe E, Schink T, Trifirò G. Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol 2016;82:487-97. [Ref.ID 100690]
6. Cita con resumen
Anónimo. FDA approves new drug treatment for nausea and vomiting from chemotherapy. U.S. Food and Drug Administration 2015:2 de septiembre. [Ref.ID 99434]
7.Tiene citas relacionadas
Campbell NL, Boustani MA. Adverse cognitive effects of medications: turning attention to reversibility. JAMA Intern Med 2015;175:408-9. [Ref.ID 98843]
8.Tiene citas relacionadas Cita con resumen
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Krane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia. A prospective cohort study. JAMA Intern Med 2015;175:401-7. [Ref.ID 98842]
9. Cita con resumen
Purhonen M, Koponen H, Tiihonen J, Tanskanen A. Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort. Pharmacoepidemiol Drug Saf 2012;21:1227-31. [Ref.ID 93992]
10. Cita con resumen
Pérez-Lloret S, Rey MV, Montastruc J-L. Syndrome des jambes sans repos: Les médicaments aussi !. 2012;19:48. [Ref.ID 93270]
11. Cita con resumen
Anónimo. Troubles de la vision des couleurs d'origine médicamenteuse. Prescrire 2012;32:113-6. [Ref.ID 92321]
12. Cita con resumen
Anónimo. Quetiapine (Seroquel) and QT-interval prolongation. Med Lett Drugs Ther 2011;53:79-80. [Ref.ID 91713]
14. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
15. Cita con resumen
Zhang Y, Baicker K, Newhouse JP. Geographic variation in the quality of prescribing. N Engl J Med 2010;363:1985-8. [Ref.ID 89675]
Anónimo. Neuroleptiques: troubles de la déglutition. Prescrire 2010;30:746-8. [Ref.ID 89217]
17.Enlace a cita original
van Noord C, Eijgelsheim M, Stricker BHCH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70:16-23. [Ref.ID 88653]
18. Cita con resumen
Anónimo. Patients âgés déments et neuroleptiques: excès de mortalité. Prescrire 2010;30:427-9. [Ref.ID 88568]
19.Tiene citas relacionadas
Tiihonen J, on behalf of all authors. Mortality in patients with schizophrenia. Author's reply. Lancet 2009;374:1592-3. [Ref.ID 87114]
20.Tiene citas relacionadas
Dervaux A, Laqueille X. Mortality in patients with schizophrenia. Lancet 2009;374:1592. [Ref.ID 87113]
Seleccionar todas
 1 a 20 de 124 siguiente >>